During the past decade, Vitreo-Retinal Associates conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 10 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vitreo-Retinal Associates" #1 sponsor was "Jaeb Center for Health Research" with 10 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "Vitreo-Retinal Associates, Michigan" with 2 trials sponsored and "Novartis Pharmaceuticals" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vitreo-Retinal Associates" #1 collaborator was "National Eye Institute (NEI)" with 8 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 2 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Vitreo-Retinal Associates" are "Diabetic Macular Edema" (14 trials), "Diabetic Retinopathy" (5 trials), "Geographic Atrophy" (4 trials), "Macular Degeneration, Age-Related" (2 trials) and "Exudative Macular Degeneration" (1 trials). Many other conditions were trialed in "Vitreo-Retinal Associates" in a lesser frequency.

Most popular intervention types in "Vitreo-Retinal Associates" are "Drug" (19 trials), "Other" (4 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Faricimab" (3 trials), "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials) and "Galegenimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Vitreo-Retinal Associates" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Vitreo-Retinal Associates". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Vitreo-Retinal Associates, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Vitreo-Retinal Associates, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".